Dicerna Pharmaceuticals

Dicerna applied its proprietary second-generation RNAi technology to discover and develop innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna went public in January 2014 and was acquired by Novo Nordisk in 2021, at which point its lead program, nedosiran (since approved as Rivfloza®) was in late-stage clinical trials